Trial By Error: More on the Royal Society of Medicine Webinar

By David Tuller, DrPH

*October is crowdfunding month at Berkeley. I conduct this project as a senior fellow in public health and journalism and the university’s Center for Global Public Health. If you would like to support the project, here’s the place:

On September 24th, the Royal Society of Medicine hosted a webinar called €œLong-COVID: Understanding the shadow of the virus.” In a previous post, I criticized one of the panelists, infectious disease expert Alastair Miller, on several grounds. He promoted graded exercise therapy, made unwarranted claims about recovery rates from CBT/GET treatments, and suggested that the PACE trial suffered only from €œbad press€ rather than methodological violations that appear to meet definitions of research misconduct.

Carolyn Chew-Graham, a professor of general practice research at Keele University in Staffordshire, also participated. Professor Chew-Graham is the main author of the Royal College of General Practitioners’ unfortunate online training program on CFS/ME, which I critiqued here. That program, METRIC, is based squarely on PACE and its so-called €œsister trial,€ the FINE trial. (Professor Chew-Graham was a co-author of the FINE trial.)

These trials, and the CBT/GET paradigm itself, are grounded in the notion that what patients say about their symptoms should be dismissed and disbelieved. To recover, patients must learn to replace negative thoughts about their abilities and energy levels with positive ones and overcome their irrational phobias about exertion. The interventions rely on the unproven hypothesis that deconditioning, and nothing pathophysiological, is the cause of the prolonged debilitating symptoms.

Professor Chew-Graham is also a prominent player in the field of so-called €œmedically unexplained symptoms.€ Since she and her colleagues identify CFS/ME as an MUS, the theoretical approaches are pretty similar. Deploying flawed research, the powerful MUS lobby in the UK has expended enormous efforts to ensure that GPs shunt off patients whose symptoms they don’t understand to psycho-behavioral interventions, rather than referring them to medical specialists.

Professor Chew-Graham and some of her MUS colleagues have a history of mis-citing a seminal paper in their claimed field of expertise–a paper that examined the cost of MUS to the UK’s National Health Service. The effect of the mis-citation is to dramatically inflate this apparent cost. The dissemination of this false data point has helped create the perception of the need for ever more services to treat MUS, which is of course beneficial to the MUS experts who mis-cited the study in the first place. Two of Professor Chew-Graham’s papers have been corrected for this embarrassing mistake. (I played a role in forcing both corrections, although I was alerted to the issues by a valued informant with a sharp attention to detail.)


Professor Chew-Graham endorses pacing

Given all that, I was surprised by Professor Chew-Graham’s relatively muted expression of support for graded activity and her explicit endorsement of pacing as a viable option. This seems to represent something of an about-face. In the webinar, she discussed a qualitative study she conducted in July and August for which she interviewed 30 so-called €œlong-haulers€–patients who reported becoming sick in the early weeks of the pandemic and continued experiencing serious symptoms.

The distress of these patients over their inability to find sensitive and appropriate medical care seemed to have created a strong impression on Professor Chew-Graham. Some or many of them were experiencing symptoms for long enough that they might have met the 2007 definition of CFS/ME from the National Institute of Health and Care Excellence. Or perhaps they would fall into the MUS category that Professor Chew-Graham has so long championed.

The recommended treatments in both cases, at least in the NHS program called Improving Access to Psychological Therapies, are psycho-behavioral interventions like CBT and GET. The list of accepted interventions does not include pacing. In fact, the PACE trial purported to have proven the ineffectiveness of pacing. Here’s a key statement about PACE from the Professor Chew-Graham’s METRIC program for GPs:

This trial shows that approaches aimed at staying within limits imposed by the illness are less effective than those that test or extend such limits€¦This trial has also shown that people with CFS/ME who had support from specialist therapists to gradually increase their activity levels were more likely to report improvements in function and symptoms at the end of the year-long study.€

In the webinar, here’s what Chew-Graham said about the patients she interviewed:

People talked about how it was really hard work trying to understand their symptoms and endure their symptoms, but also trying to seek help for their symptoms. People described not being believed. A key finding was that participants in my study said it’s really important to find the right GP. [They said] ‘I need to be believed, I need to be taken seriously, the GP I talk to needs to have empathy and understanding and not dismiss my concerns’€¦The people I talked to in my interviews very much said they had only a small amount of energy and during the recovery phase they felt they had to stick within this and that the post-exertional fatigue was tremendous.

Professor Chew-Graham comes across as extremely concerned about these patients and their distress at being dismissed. She appears to believe that they should be trusted to know their own energy limits. She does not explain why that sensible approach does not apply with CFS/ME and MUS, even though some of the patients she interviewed might have already met criteria for those diagnoses. And why does Professor Chew-Graham endorse pacing as a strategy for patients experiencing post-Covid symptoms but argue against it for patients with what she and her colleagues tend to call CFS/ME? In light of her new qualitative data, perhaps she will revisit her previous publications and reassess her commitment to the CBT/GET approach.

In the webinar, Professor Chew-Graham agreed Miller, the infectious disease experts, that patients with specific organ damage needed to be differentiated from those experiencing a standard “post-viral syndrome.” But she expressed concern that patients had limited access to the suite of specialist diagnostic and rehabilitation services needed to make the appropriate determinations and develop treatment plans with confidence. Given that and the many medical unknowns, she said, it’s €œa frightening position for patients to be in but also for GPs to be in.€

What explains Professor Chew-Graham’s apparent shift? Perhaps she is simply responding to the stories of sympathetic interview subjects. Maybe it’s because this is a new illness and these are still short-term patients and so what is said about them doesn’t apply to CFS/ME or MUS patients, who have often been ill for years. Perhaps, a year from now, she would advise post-Covid patients who did not have specific organ damage yet still suffered from fatigue and other non-specific symptoms that they had CFS/ME and needed to forget about pacing and get some CBT or GET.

On the other hand, perhaps she now has a deeper awareness that an inability to explain patients’ symptoms, while likely €œa frightening position€ for GPs, does not justify the presumption of unhelpful illness beliefs and deconditioning that characterizes the CBT/GET paradigm. In any event, does Professor Chew-Graham recognize the apparent discordance between what she said in the webinar and what she has written about CBT/GET, MUS and the like for years? It would be interesting to find out.

Comments are closed.

Scroll to Top